1,606 Shares in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Acquired by Wingate Wealth Advisors Inc.

Wingate Wealth Advisors Inc. purchased a new position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) during the fourth quarter, Holdings Channel reports. The firm purchased 1,606 shares of the biopharmaceutical company’s stock, valued at approximately $53,000.

A number of other hedge funds have also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. grew its stake in Agios Pharmaceuticals by 10.5% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 12,092 shares of the biopharmaceutical company’s stock worth $397,000 after buying an additional 1,150 shares during the last quarter. KBC Group NV grew its stake in shares of Agios Pharmaceuticals by 30.5% in the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock valued at $86,000 after purchasing an additional 611 shares during the last quarter. Inspire Investing LLC grew its stake in shares of Agios Pharmaceuticals by 34.2% in the 4th quarter. Inspire Investing LLC now owns 12,384 shares of the biopharmaceutical company’s stock valued at $407,000 after purchasing an additional 3,156 shares during the last quarter. Contravisory Investment Management Inc. purchased a new position in shares of Agios Pharmaceuticals in the 4th quarter valued at approximately $222,000. Finally, Nordea Investment Management AB grew its stake in shares of Agios Pharmaceuticals by 3.6% in the 4th quarter. Nordea Investment Management AB now owns 220,569 shares of the biopharmaceutical company’s stock valued at $7,191,000 after purchasing an additional 7,593 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. StockNews.com upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, November 9th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. Royal Bank of Canada lifted their target price on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. Finally, Scotiabank lifted their target price on Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a research note on Monday, December 9th. Five equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Agios Pharmaceuticals currently has an average rating of “Hold” and an average price target of $56.33.

Insider Activity at Agios Pharmaceuticals

In related news, insider Tsveta Milanova sold 2,804 shares of Agios Pharmaceuticals stock in a transaction on Monday, January 6th. The stock was sold at an average price of $32.18, for a total transaction of $90,232.72. Following the completion of the transaction, the insider now directly owns 18,906 shares of the company’s stock, valued at approximately $608,395.08. The trade was a 12.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 4.93% of the company’s stock.

Agios Pharmaceuticals Price Performance

Agios Pharmaceuticals stock opened at $33.97 on Tuesday. Agios Pharmaceuticals, Inc. has a 1-year low of $24.69 and a 1-year high of $62.58. The company has a market cap of $1.94 billion, a PE ratio of 2.99 and a beta of 0.88. The stock’s 50 day moving average price is $37.33 and its 200 day moving average price is $43.76.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.